MBX Biosciences, Inc. | LinkedIn (original) (raw)

``

Biotechnology Research

Carmel, IN 6,958 followers

Advancing potential breakthrough medicines for endocrine diseases of substantial medical need.

About us

MBX Biosciences, Inc. is a clinical stage biopharmaceutical company pioneering investigational Precision Endocrine Peptides (PEPs™). PEPs are designed to overcome key limitations of native peptide therapeutics to deliver superior pharmacologic properties. MBX is advancing a pipeline of PEP candidates to address the unmet needs of people with endocrine disorders. The company’s lead product candidate, MBX 2109 for the treatment of hypoparathyroidism, is currently in a Phase 1 clinical trial. Members of MBX’s leadership team have collaborated over several decades on the discovery, development, and commercialization of highly successful endocrine therapeutics including Forteo® and Humalog®. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates and OrbiMed.

Industry

Biotechnology Research

Company size

11-50 employees

Headquarters

Carmel, IN

Type

Privately Held

Founded

2019

Locations

Employees at MBX Biosciences, Inc.

Updates

Join now to see what you are missing

Join now

Similar pages

Browse jobs

Funding